First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study

First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study / Necchi, A; Lo Vullo, S; Perrone, F; Raggi, D; Giannatempo, P; Calareso, G; Nicolai, N; Piva, L; Biasoni, D; Catanzaro, M; Torelli, T; Stagni, S; Togliardi, E; Colecchia, M; Busico, A; Gloghini, A; Testi, A; Mariani, L; Salvioni, R. - In: BJU INTERNATIONAL. - ISSN 1464-4096. - 121:3(2018), pp. 348-356. [10.1111/bju.14013]